PDCD1 and head and neck neoplasm: Although the expression of PD-L2 in head and neck tumors can be associated with an enhanced PD1-mediated T-cell response [30], PD-L2 is not considered a significant immunotherapy target in the clinic compared to PD-L1, the predominant inhibitory ligand of PD1 [20].